



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

March 21, 2006

Docket No. 03005357
Control No. 138279

License No. 29-08978-02

Ronald Califre
Senior Vice President, R&D Operations
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080

SUBJECT: NOVARTIS PHARMACEUTICALS CORPORATION, REQUEST FOR
ADDITIONAL INFORMATION CONCERNING FINANCIAL ASSURANCE
DOCUMENTS, CONTROL NO. 138279

Dear Mr. Califre:

There was an audit performed which reviewed the financial assurance for decommissioning for Nuclear Regulatory Commission License No. 29-08978-02. It was discovered that the Certificate of Resolution was not in accordance with our guidance. In order to continue our review, we need the following additional information:

1. The current Certificate of Resolution does not comply with the guidance as given in model specimen certificate of resolution on page A-167 of NUREG-1757, Volume 3, "Financial Assurance, Recordkeeping, and Timeliness." The certificate of resolution should not be signed like the currently submitted certificate. The purpose of the certificate is to fulfill the requirements in item 3 of the Certificate of Events. This section states the Board of Directors of Novartis Pharmaceuticals Corporation has adopted the attached resolution authorizing the commencement of the decommissioning. Please submit a Certificate of Resolution that closely follows the model specimen and is not signed.

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Industrial, and Academic Uses of Nuclear Material**; then **Toolkit Index Page**. Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 9:00 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 138279. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5366.

R. Califre
Novartis Pharmaceuticals Corporation

2

Sincerely,

Original signed by Dennis R. Lawyer

Dennis R. Lawyer
Health Physicist
Commercial and R&D Branch
Division of Nuclear Materials Safety

cc:
George Stone, Radiation Safety Officer

DOCUMENT NAME: E:\Filenet\ML060820384.wpd

SISP Review Complete: DLawyer

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	<input checked="" type="checkbox"/> N	DNMS/RI	<input type="checkbox"/>	DNMS/RI	<input type="checkbox"/>		
NAME	DLawyer /DRL1/							
DATE	03/21/2006							

OFFICIAL RECORD COPY